Skip to main content
$49.69 -$3.68 (-6.9%)

04:00 PM EDT on 10/15/21

Cassava Sciences, Inc. (NASDAQ:SAVA)

CAPS Rating: 2 out of 5

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Current Price $49.69 Mkt Cap $2.0B
Open $54.00 P/E Ratio 0.00
Prev. Close $49.69 Div. (Yield) $0.00 (0.0%)
Daily Range $49.60 - $54.00 Volume 3,747,611
52-Wk Range $6.70 - $146.16 Avg. Daily Vol. 9,302,147

Caps

How do you think NASDAQ:SAVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

195 Outperform
34 Underperform
 

All-Star Players

32 Outperform
9 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:SAVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Simbalion200 (< 20)
Submitted April 09, 2010

Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. As of December 31, 2009, the Company had four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a radio-labeled monoclonal antibody to treat… More

SmartAce (98.46)
Submitted August 27, 2018

My 5 year old son just asked “what if we put a slice of turkey in the DVD player and it played a movie about the turkey’s whole life” and none of the parenting books I’ve read have prepared me for this question.

Recent Community Commentary

Read the most recent pitches from players about SAVA.

Recs

0
Member Avatar ToeKneeNose (44.54) Submitted: 7/30/2021 1:33:54 PM : Outperform Start Price: $75.16 NASDAQ:SAVA Score: -34.50

Just cuz

Recs

0
Member Avatar wpshil78 (32.98) Submitted: 7/22/2021 10:06:08 AM : Outperform Start Price: $119.37 NASDAQ:SAVA Score: -60.41

It's one drug candidate, Simufilam, looks like it's effective in the treatment of Alzheimers'. Phase III endpoints to be presented during the Summer 2021. This drug has massive potential.

Recs

0
Member Avatar TMFjimhalley (< 20) Submitted: 7/12/2021 6:46:55 PM : Outperform Start Price: $100.15 NASDAQ:SAVA Score: -51.87

The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.

Leaderboard

Find the members with the highest scoring picks in SAVA.

Score Leader

medeaschild

medeaschild (70.58) Score: +6,432.03

The Score Leader is the player with the highest score across all their picks in SAVA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
medeaschild 70.58 12/26/2018 Outperform NS $0.76 +6,520.89% +88.86% +6,432.03 0 Comment
SmallCapSurfer2 95.88 10/13/2016 Outperform 3M $5.32 +846.71% +110.06% +736.66 0 Comment
capptten < 20 12/1/2020 Outperform 3M $7.66 +557.51% +21.91% +535.60 1 Comment
foolrrrrrrrrrr 28.36 11/13/2008 Underperform 1Y $37.61 +33.93% +441.05% +407.13 0 Comment
jornoski 53.07 9/21/2020 Outperform 5Y $9.45 +432.96% +36.83% +396.13 0 Comment
OklaBoston 65.05 9/21/2020 Outperform 3Y $9.45 +432.96% +36.83% +396.13 1 Comment
clangmead 53.74 1/19/2021 Outperform 5Y $10.38 +385.21% +17.79% +367.42 0 Comment
Dennyf10 62.32 10/16/2008 6/22/2009 Underperform 1Y $35.72 +40.98% +399.47% +358.49 0 Comment
marcet 74.22 3/2/2009 Underperform 3W $18.82 +167.55% +525.43% +357.87 0 Comment
hackerbobZ < 20 3/23/2009 Underperform 5Y $17.65 +185.31% +471.90% +286.59 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SAVA.